WebNov 15, 2010 · The primary objective in the Phase II portion is to compare the combination crolibulin plus cisplatin versus cisplatin alone in adults with ATC by assessing the duration of progression-free survival (PFS); comparison of the response rates as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) will be an important secondary … WebAug 8, 2010 · Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. How cells respond to cisplatin-induced DNA damage plays a critical role in deci …
WHOCC - ATC/DDD Index
WebSep 1, 2024 · Cisplatin, the active ingredient in Cisplatin for injection, USP, is a yellow to orange crystalline powder with the molecular formulaCl 2 H 6 N 2 Pt and a molecular weight of 300.05. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. WebOxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication ( platinum-based antineoplastic class) used to treat colorectal cancer. [3] It is given by injection into a vein. [3] Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts. inch kochel ays sere 29
Cisplatin 1 mg/ml Sterile Concentrate - Summary of …
WebJul 10, 2024 · The compliance to adjuvant cisplatin and gemcitabine was suboptimal because only 84.6% of patients randomly assigned to adjuvant chemotherapy actually started treatment, and 65.4%, 57.7%, and 50.0% completed four, five, and six cycles of adjuvant cisplatin and gemcitabine, respectively (Appendix Table A3). The reasons for … WebCisplatin Indications/Uses Palliative therapy either alone or in combination w/ other chemotherapeutic against & in patients who already received surgical &/or … WebAug 11, 2024 · Gemcitabine plus cisplatin (GP) has become the preferred first-line treatment option for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), based on the improvement in progression-free survival (PFS) with GP compared to fluorouracil plus cisplatin (FP). Could this be translated into long-term survival benefit? inch kochel ays sere 27